Scholarlink

Background <p>Hookworms, specifically <i>Ancylostoma caninum</i> and <i>Uncinaria stenocephala</i>, have a clinical impact on the health of dogs, with <i>A.&#xa0;caninum</i> posing a zoonotic risk worldwide. The studies presented here were conducted to evaluate the efficacy of a novel, oral chewable tablet (Credelio Quattro) containing lotilaner, moxidectin, praziquantel, and pyrantel (as pamoate salt) against fourth-stage larvae (L<sub>4</sub>), immature adult, and adult <i>A.&#xa0;caninum</i>, as well as adult <i>U.&#xa0;stenocephala</i>, infections in dogs.</p> Methods <p>Nine negatively controlled, masked, randomized laboratory studies evaluated the efficacy and non-interference of the drugs against various stages of <i>A.&#xa0;caninum</i> and <i>U.&#xa0;stenocephala</i>. In addition to one pilot study conducted against L<sub>4</sub> <i>A</i>.&#xa0;<i>caninum</i> and one study that assessed efficacy in dogs with naturally acquired <i>U.&#xa0;stenocephala</i>, two experimental studies were conducted against each of the target hookworm species and stages. A total of 16–31 dogs comprised each study. With the exception of the study in dogs with naturally acquired <i>U.&#xa0;stenocephala</i>, dogs were experimentally infected with the target parasite and dosed on Day 0 or 4 with placebo tablets, Credelio Quattro tablets (or components of Credelio Quattro formulation for the pilot study), or individual actives, moxidectin or pyrantel, in the specific studies designed to assess interference. Efficacy was evaluated by comparing the number of worms recovered at necropsy 5–10&#xa0;days post-treatment between the treated and control groups.</p> Results <p>All dogs tolerated Credelio Quattro well. Efficacy of Credelio Quattro was ≥ 99.0% against L<sub>4</sub> <i>A.&#xa0;caninum</i>, ≥ 99.8% against immature adult <i>A.&#xa0;caninum</i>, ≥ 99.9% against adult <i>A.&#xa0;caninum</i>, and ≥ 99.6% against adult <i>U.&#xa0;stenocephala.</i> Additionally, treatment with Credelio Quattro provided a ≥ 99.9% reduction in fecal egg counts 10&#xa0;days post-treatment.</p> Conclusions <p>Credelio Quattro, a novel oral chewable tablet administered at the minimum effective dosages of 20&#xa0;mg/kg lotilaner, 0.02&#xa0;mg/kg moxidectin, 5.0&#xa0;mg/kg praziquantel, and 5.0&#xa0;mg/kg pyrantel (as pamoate salt), was safe and effective for the treatment and control of L<sub>4</sub>, immature adult, and adult stages of <i>A.&#xa0;caninum</i> and adult <i>U.&#xa0;stenocephala</i> in dogs.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the treatment and control of hookworm infections in dogs

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月2日

查看全文
  • Samuel Charles,
  • Katrin Deuster,
  • Xinshuo Wang,
  • Scott Wiseman,
  • Craig R. Reinemeyer,
  • Luther van der Mescht,
  • Abdelmoneim Mansour,
  • Imad Bouzaidi Cheikhi,
  • Lisa Young

摘要

Background

Hookworms, specifically Ancylostoma caninum and Uncinaria stenocephala, have a clinical impact on the health of dogs, with A. caninum posing a zoonotic risk worldwide. The studies presented here were conducted to evaluate the efficacy of a novel, oral chewable tablet (Credelio Quattro) containing lotilaner, moxidectin, praziquantel, and pyrantel (as pamoate salt) against fourth-stage larvae (L4), immature adult, and adult A. caninum, as well as adult U. stenocephala, infections in dogs.

Methods

Nine negatively controlled, masked, randomized laboratory studies evaluated the efficacy and non-interference of the drugs against various stages of A. caninum and U. stenocephala. In addition to one pilot study conducted against L4 A. caninum and one study that assessed efficacy in dogs with naturally acquired U. stenocephala, two experimental studies were conducted against each of the target hookworm species and stages. A total of 16–31 dogs comprised each study. With the exception of the study in dogs with naturally acquired U. stenocephala, dogs were experimentally infected with the target parasite and dosed on Day 0 or 4 with placebo tablets, Credelio Quattro tablets (or components of Credelio Quattro formulation for the pilot study), or individual actives, moxidectin or pyrantel, in the specific studies designed to assess interference. Efficacy was evaluated by comparing the number of worms recovered at necropsy 5–10 days post-treatment between the treated and control groups.

Results

All dogs tolerated Credelio Quattro well. Efficacy of Credelio Quattro was ≥ 99.0% against L4 A. caninum, ≥ 99.8% against immature adult A. caninum, ≥ 99.9% against adult A. caninum, and ≥ 99.6% against adult U. stenocephala. Additionally, treatment with Credelio Quattro provided a ≥ 99.9% reduction in fecal egg counts 10 days post-treatment.

Conclusions

Credelio Quattro, a novel oral chewable tablet administered at the minimum effective dosages of 20 mg/kg lotilaner, 0.02 mg/kg moxidectin, 5.0 mg/kg praziquantel, and 5.0 mg/kg pyrantel (as pamoate salt), was safe and effective for the treatment and control of L4, immature adult, and adult stages of A. caninum and adult U. stenocephala in dogs.

Graphical Abstract